Jim Haggerty interviewed in Adweek on Johnson & Johnson’s response to cancer claims
PRCG CEO Jim Haggerty addresses weaknesses in Johnson & Johnson’s response to the $72 million order linking the plaintiff’s death from ovarian cancer with her usage of products containing talcum. He contrasts this response with Lumber Liquidators’ more consumer-focused approach.
“They clearly were unprepared for what to do if there was a big verdict,” said James Haggerty, president and CEO of PRCG Haggerty. “The blog post feels like it’s written by a combination of scientists and lawyers.”